Nupotential's proprietary PIER (tm) drug discovery platform stems from the foundational discoveries of Dr. Kenneth Eilertsen linking small molecule epigenetic pathway modulators to cellular reprogramming. Imbedded in this breakthrough was the uncovering that modifying a single biochemical pathway could alter key epigenetic modifications. NuPotential's proprietary understandings of key epigenetic pathways and related biology have elicited attractive drug targets and formed the basis for select, novel drug discovery strategies. 

NuPotential has identified several promising epigenetic targets and candidate molecules from which to investigate lead series compounds. These lead molecules have demonstrated high selectivity across histone and DNA methylation isoforms and promising efficacy in enzymatic and challenging in-vitro tumors models, e.g. triple negative breast cancer cell lines, a cancer form for which there is no currently available treatments. Forthcoming R&D efforts will expand, advance and further characterize these candidates for tumor type potential, safety, pharmaceutics and efficacy and select prioritized compounds for clinical development.